However, the clinical efficacy of Tmab against human pancreatic carcinoma is inadequate [24] because it was usually investigated in HER2-high-expressing cell lines [26–28], whereas most human pancreatic cancers express only low levels of HER2 [22]. Here, ERBB2 is linked to pancreatic neoplasm.